
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Recommendations for using ruxolitinib to treat a 53-year-old patient with acute graft-versus-host disease whose disease progresses following previous treatment with steroid therapy.
Case: A 53-Year-Old Man With Steroid-Refractory Acute Graft-Versus-Host Disease
Initial presentation
Clinical workup
Treatment